Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review

References

• Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE. 2012;7(5):e35671.10.1371/journal.pone.0035671
   PubMed Web of Science ®Google Scholar
• Karimkhani C, Wanga V, Coffeng LE, Naghavi P, Dellavalle RP, Naghavi M. Global burden of cutaneous leishmaniasis: a cross-sectional analysis from the Global Burden of Disease Study 2013. Lancet Infect Dis. 2016; 16(5): 584–91.
   PubMed Web of Science ®Google Scholar
• Kaye P, Scott P. Leishmaniasis: complexity at the host-pathogen interface. Nat Rev Microbiol. 2011;9(8):604–15.10.1038/nrmicro2608
   PubMed Web of Science ®Google Scholar
• Sacks D, Kamhawi S. Molecular aspects of parasite-vector and vector-host interactions in leishmaniasis. Annu Rev Microbiol. 2001;55:453–83.10.1146/annurev.micro.55.1.453
   PubMed Web of Science ®Google Scholar
• Scott, P, Novais, FO. Cutaneous leishmaniasis: immune responses in protection and pathogenesis. Nat Rev Immunol. 2016; 16(9): 581–92.
   PubMed Web of Science ®Google Scholar
• Bailey MS, Lockwood DN. Cutaneous leishmaniasis. Clin Dermatol. 2007;25(2):203–11.10.1016/j.clindermatol.2006.05.008
   PubMed Web of Science ®Google Scholar
• von Stebut E, Ehrchen JM, Belkaid Y, Kostka SL, Mölle K, Knop J, et al. Interleukin 1α promotes Th(1) differentiation and inhibits disease progression in Leishmania major – susceptible BALB/c mice. J Exp Med. 2003;198(2):191–99.10.1084/jem.20030159
   PubMed Web of Science ®Google Scholar
• Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol. 2002;2(11):845–58.10.1038/nri933
   PubMed Web of Science ®Google Scholar
• Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3(1):23–35.10.1038/nri978
   PubMed Web of Science ®Google Scholar
• Kropf P, Fuentes JM, Fahnrich E, Arpa L, Herath S, Weber V, et al. Arginase and polyamine synthesis are key factors in the regulation of experimental leishmaniasis in vivo. Faseb J. 2005;19(8):1000–02.
   PubMed Web of Science ®Google Scholar
• Nylén S, Eidsmo L. Tissue damage and immunity in cutaneous leishmaniasis. Parasite Immunol. 2012;34(12):551–61.10.1111/pim.12007
   PubMed Web of Science ®Google Scholar
• Martin P, Leibovich SJ. Inflammatory cells during wound repair: the good, the bad and the ugly. Trend Cell Biol. 2005;15(11):599–607.10.1016/j.tcb.2005.09.002
   PubMed Web of Science ®Google Scholar
• Eming SA, Krieg T, Davidson JM. Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol. 2007;127(3):514–25.10.1038/sj.jid.5700701
   PubMed Web of Science ®Google Scholar
• Borthwick LA, Wynn TA, Fisher AJ. Cytokine mediated tissue fibrosis. BBA-Mol Basis Dis. 2013;1832(7):1049–60.10.1016/j.bbadis.2012.09.014
   PubMed Web of Science ®Google Scholar
• Pasparakis M, Haase I, Nestle FO. Mechanisms regulating skin immunity and inflammation. Nat Rev Immunol. 2014;14(5):289–301.10.1038/nri3646
   PubMed Web of Science ®Google Scholar
• Allen JE, Wynn TA. Evolution of Th2 Immunity: a rapid repair response to tissue destructive pathogens. PLoS Pathogens. 2011;7(5):e1002003.10.1371/journal.ppat.1002003
   PubMed Web of Science ®Google Scholar
• Gause WC, Wynn TA, Allen JE. Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths. Nat Rev Immunol. 2013;13(8):607–14.10.1038/nri3476
   PubMed Web of Science ®Google Scholar
• Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol. 2008;8(4):247–58.10.1038/nri2274
   PubMed Web of Science ®Google Scholar
• Wu W, Huang L, Mendez S. A live Leishmania major vaccine containing CpG motifs induces the de novo generation of Th17 cells in C57BL/6 mice. Eur J Immunol. 2010;40(9):2517–27.10.1002/eji.201040484
   PubMed Web of Science ®Google Scholar
• Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 2007;96:41–101.10.1016/S0065-2776(07)96002-2
   PubMed Web of Science ®Google Scholar
• Sharma U, Singh S. Immunobiology of leishmaniasis. Indian J Exp Biol. 2009;47(6):412–23.
   PubMed Web of Science ®Google Scholar
• Alexander J, Satoskar AR, Russell DG. Leishmania species: models of intracellular parasitism. J Cell Sci. 1999;112(18):2993–3002.
   PubMed Web of Science ®Google Scholar
• Pinheiro RO, Rossi-Bergmann B. Interferon-gamma is required for the late but not early control of Leishmania amazonensis infection in C57Bl/6 mice. Mem Inst Oswaldo Cruz. 2007;102(1):79–82.10.1590/S0074-02762007000100013
   PubMed Web of Science ®Google Scholar
• Liew FY, Wei XQ, Proudfoot L. Cytokines and nitric oxide as effector molecules against parasitic infections. Philos Trans R Soc Lond B Biol Sci. 1997;352(1359):1311–15.10.1098/rstb.1997.0115
   PubMed Web of Science ®Google Scholar
• Wilhelm P, Ritter U, Labbow S, Donhauser N, Rollinghoff M, Bogdan C, et al. Rapidly fatal leishmaniasis in resistant C57BL/6 mice lacking tnf. J Immunol. 2001;166(6):4012–19.10.4049/jimmunol.166.6.4012
   PubMed Web of Science ®Google Scholar
• Theodos CM, Povinelli L, Molina R, Sherry B, Titus RG. Role of tumor necrosis factor in macrophage leishmanicidal activity in vitro and resistance to cutaneous leishmaniasis in vivo. Infect Immune. 1991;59(8):2839–42.
   PubMed Web of Science ®Google Scholar
• Garcia I, Miyazaki Y, Araki K, Araki M, Lucas R, Grau GE, et al. Transgenic mice expressing high levels of soluble TNF-R1 fusion protein are protected from lethal septic shock and cerebral malaria, and are highly sensitive to Listeria monocytogenes and Leishmania major infections. Eur J Immunol. 1995;25(8):2401–07.10.1002/(ISSN)1521-4141
   PubMed Web of Science ®Google Scholar
• Liew FY, Li Y, Millott S. Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol. 1990;145(12):4306–10.
   PubMed Web of Science ®Google Scholar
• Gaafar A, Veress B, Permin H, Kharazmi A, Theander TG, El Hassan AM. Characterization of the local and systemic immune responses in patients with cutaneous leishmaniasis due to Leishmania major. Clin Immunol. 1999;91(3):314–20.10.1006/clim.1999.4705
   PubMed Web of Science ®Google Scholar
• Pompeu MM, Brodskyn C, Teixeira MJ, Clarencio J, Van Weyenberg J, Coelho IC, et al. Differences in gamma interferon production in vitro predict the pace of the in vivo response to Leishmania amazonensis in healthy volunteers. Infect Immun. 2001;69(12):7453–60.10.1128/IAI.69.12.7453-7460.2001
   PubMed Web of Science ®Google Scholar
• Antonelli LRV, Dutra WO, Almeida RP, Bacellar O, Gollob KJ. Antigen specific correlations of cellular immune responses in human leishmaniasis suggests mechanisms for immunoregulation. Clin Exp Immunol. 2004;136(2):341–8.10.1111/cei.2004.136.issue-2
   PubMed Web of Science ®Google Scholar
• Oliveira F, Bafica A, Rosato AB, Favali CB, Costa JM, Cafe V, et al. Lesion size correlates with Leishmania antigen-stimulated TNF-levels in human cutaneous leishmaniasis. Am J Trop Med Hyg. 2011;85(1):70–3.10.4269/ajtmh.2011.10-0680
   PubMed Web of Science ®Google Scholar
• D'Oliveira Junior A Jr., Machado P, Bacellar O, Cheng LH, Almeida RP, Carvalho EM. Evaluation of IFN-gamma and TNF-alpha as immunological markers of clinical outcome in cutaneous leishmaniasis. Rev Soc Bras Med Trop. 2002;35(1):7–10.10.1590/S0037-86822002000100002
   PubMedGoogle Scholar
• Bacellar O, Lessa H, Schriefer A, Machado P, Ribeiro de Jesus A, Dutra WO, et al. Up-Regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun. 2002;70(12):6734–40.10.1128/IAI.70.12.6734-6740.2002
   PubMed Web of Science ®Google Scholar
• Antonelli LR, Dutra WO, Almeida RP, Bacellar O, Carvalho EM, Gollob KJ. Activated inflammatory T cells correlate with lesion size in human cutaneous leishmaniasis. Immunol Lett. 2005;101(2):226–30.10.1016/j.imlet.2005.06.004
   PubMed Web of Science ®Google Scholar
• Ivonise F, Cibele A, Olívia B, Clarissa BA, Lucas PC, Roque PA, et al. Epidemiologic and Immunologic Findings for the Subclinical Form of Leishmania braziliensis Infection. Clin Infect Dis. 2002;34(11):e54–e8.
   PubMed Web of Science ®Google Scholar
• Carvalho EM, Johnson WD, Barreto E, Marsden PD, Costa JL, Reed S, et al. Cell mediated immunity in American cutaneous and mucosal leishmaniasis. J Immunol. 1985;135(6):4144–48.
   PubMed Web of Science ®Google Scholar
• Ribeiro-de-Jesus A, Almeida RP, Lessa H, Bacellar O, Carvalho EM. Cytokine profile and pathology in human leishmaniasis. Braz J Med Biol Res. 1998;31(1):143–8.10.1590/S0100-879X1998000100020
   PubMed Web of Science ®Google Scholar
• Oliveira WN, Ribeiro LE, Schrieffer A, Machado P, Carvalho EM, Bacellar O. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of human tegumentary leishmaniasis. Cytokine. 2014;66(2):127–32.10.1016/j.cyto.2013.12.016
   PubMed Web of Science ®Google Scholar
• Güler ML, Gorham JD, Hsieh C-S, Mackey AJ, Steen RG, Dietrich WF, et al. Genetic susceptibility to leishmania: IL-12 responsiveness in TH1 cell development. Science. 1996;271(5251):984–7.10.1126/science.271.5251.984
   PubMed Web of Science ®Google Scholar
• Constantinescu CS, Hondowicz BD, Elloso MM, Wysocka M, Trinchieri G, Scott P. The role of IL-12 in the maintenance of an established Th1 immune response in experimental leishmaniasis. Eur J Immunol. 1998;28(7):2227–33.10.1002/(ISSN)1521-4141
   PubMed Web of Science ®Google Scholar
• Sypek JP, Chung CL, Mayor SE, Subramanyam JM, Goldman SJ, Sieburth DS, et al. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med. 1993;177(6):1797–1802.10.1084/jem.177.6.1797
   PubMed Web of Science ®Google Scholar
• Palmer EM, Farrokh-Siar L, Maguire van Seventer J, Van Seventer, GA. IL-12 Decreases activation-induced cell death in human naive Th Cells costimulated by intercellular adhesion molecule-1. I. IL-12 alters caspase processing and inhibits enzyme function. J Immunol. 2001;167(2):749–58.10.4049/jimmunol.167.2.749
   PubMed Web of Science ®Google Scholar
• Mullen AC, High FA, Hutchins AS, Lee HW, Villarino AV, Livingston DM, et al. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science. 2001;292(5523):1907–10.10.1126/science.1059835
   PubMed Web of Science ®Google Scholar
• Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu Rev Immunol. 1998;16:495–521.10.1146/annurev.immunol.16.1.495
   PubMed Web of Science ®Google Scholar
• Mal, X, Trinchieri, G. Regulation of interleukin-12 production in antigen-presenting cells. Adv Immunol. 2001;79:55–92.10.1016/S0065-2776(01)79002-5
   PubMed Web of Science ®Google Scholar
• Vignali DA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol. 2012;13(8):722–8.10.1038/ni.2366
   PubMed Web of Science ®Google Scholar
• Gee K, Guzzo C, Che Mat NF, Ma W, Kumar A. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets. 2009;8(1):40–52.10.2174/187152809787582507
   PubMedGoogle Scholar
• Park AY, Hondowicz B, Kopf M, Scott P. The role of IL-12 in maintaining resistance to Leishmania major. J Immunol. 2002;168(11):5771–77.10.4049/jimmunol.168.11.5771
   PubMed Web of Science ®Google Scholar
• Mattner F, Magram J, Ferrante J, Launois P, Padova K, Behin R, et al. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol. 1996;26(7):1553–59.10.1002/(ISSN)1521-4141
   PubMed Web of Science ®Google Scholar
• Teng MWL, Bowman EP, McElwee JJ, Smyth MJ, Casanova J-L, Cooper AM, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21(7):719–29.10.1038/nm.3895
   PubMed Web of Science ®Google Scholar
• Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, et al. A receptor for the Heterodimeric cytokine IL-23 Is Composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168(11):5699–708.10.4049/jimmunol.168.11.5699
   PubMed Web of Science ®Google Scholar
• Afonso L, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science. 1994;263(5144):235–7.10.1126/science.7904381
   PubMed Web of Science ®Google Scholar
• Kenney RT, Sacks DL, Sypek JP, Vilela L, Gam AA, Evans-Davis K. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol. 1999;163(8):4481–8.
   PubMed Web of Science ®Google Scholar
• Maspi, N, Ghaffarifar, F, Sharifi, Z, Dalimi, A. Co-delivery of DNA vaccination encoding LeIF gene and IL-12 increases protection against Leishmania major infection in BALB/c mice. Parasit Immunol. 2016;38(4):228–35.
   PubMed Web of Science ®Google Scholar
• Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med. 1993;177(5):1505–09.10.1084/jem.177.5.1505
   PubMed Web of Science ®Google Scholar
• Malek TR. The biology of interleukin-2. Annu Rev Immunol. 2008;26:453–79.10.1146/annurev.immunol.26.021607.090357
   PubMed Web of Science ®Google Scholar
• Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med. 2005;201(5):723–35.10.1084/jem.20041982
   PubMed Web of Science ®Google Scholar
• Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180–90.
   PubMed Web of Science ®Google Scholar
• Gaffen SL, Liu KD. Overview of interleukin-2 function, production and clinical applications. Cytokine. 2004;28(3):109–23.10.1016/j.cyto.2004.06.010
   PubMed Web of Science ®Google Scholar
• Smith KA. Interleukin-2: inception, impact, and implications. Science. 1988;240(4856):1169–76.10.1126/science.3131876
   PubMed Web of Science ®Google Scholar
• Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol. 2004;172(7):3983–8.10.4049/jimmunol.172.7.3983
   PubMed Web of Science ®Google Scholar
• Malek TR, Yu A, Vincek V, Scibelli P, Kong L. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rβ-deficient mice: implications for the nonredundant function of IL-2. Immunity. 2002;17(2):167–78.10.1016/S1074-7613(02)00367-9
   PubMed Web of Science ®Google Scholar
• Malek TR, Porter BO, Codias EK, Scibelli P, Yu A. Normal lymphoid homeostasis and lack of lethal autoimmunity in mice containing mature T cells with severely impaired IL-2 receptors. J Immunol. 2000;164(6):2905–14.10.4049/jimmunol.164.6.2905
   PubMed Web of Science ®Google Scholar
• Malek TR. The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol. 2003;74(6):961–5.10.1189/jlb.0603272
   PubMed Web of Science ®Google Scholar
• Wang X, Mosmann T. In vivo priming of CD4 T cells that produce interleukin (IL)-2 but not IL-4 or interferon (IFN)-gamma, and can subsequently differentiate into IL-4- or IFN-gamma-secreting cells. J Exp Med. 2001;194(8):1069–80.10.1084/jem.194.8.1069
   PubMed Web of Science ®Google Scholar
• Mashayekhi Goyonlo V, Elnour H, Nordlind K. Interleukin-2 expression in lupoid and usual types of old world cutaneous leishmaniasis. Iran Red Crescent Med J. 2014;16(11):e5410.
   PubMed Web of Science ®Google Scholar
• Oliveira PR, Dessein H, Romano A, Cabantous S, de Brito ME, Santoro F, et al. IL2RA genetic variants reduce IL-2-dependent responses and aggravate human cutaneous leishmaniasis. J Immunol. 2015;194(6):2664–72.10.4049/jimmunol.1402047
   PubMed Web of Science ®Google Scholar
• Espir TT, de Paula Figueira L, de Farias Naiff M, da Costa AG, Ramalho-Ortigão M, Malheiro A, et al. The role of inflammatory, anti-inflammatory, and regulatory cytokines in patients infected with cutaneous leishmaniasis in amazonas state, Brazil. J Immunol Res. 2014;2014:10. doi:10.1155/2014/481750
   Web of Science ®Google Scholar
• Divanovic, S, Trompette, A, Ashworth, JI, Rao, MB, Karp, CL. Therapeutic enhancement of protective immunity during experimental leishmaniasis. PLoS Negl Trop Dis. 2011;5(9). doi:10.1371/journal.pntd.0001316.
   PubMed Web of Science ®Google Scholar
• Le Gros G, Ben-Sasson SZ, Seder R, Finkelman F, Paul W. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells. J Exp Med. 1990;172(3):921–9.10.1084/jem.172.3.921
   PubMed Web of Science ®Google Scholar
• Kondo M, Takeshita T, Ishii N, Nakamura M, Watanabe S, Arai K, et al. Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science. 1993;262(5141):1874–77.10.1126/science.8266076
   PubMed Web of Science ®Google Scholar
• Russell SM, Keegan AD, Harada N, Nakamura Y, Noguchi M, Leland P, et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor. Science. 1993;262(5141):1880–3.10.1126/science.8266078
   PubMed Web of Science ®Google Scholar
• Heinzel FP, Rerko RM, Hatam F, Locksley RM. IL-2 is necessary for the progression of leishmaniasis in susceptible murine hosts. J Immunol. 1993;150(9):3924–31.
   PubMed Web of Science ®Google Scholar
• Apte RN, Voronov E. Is interleukin-1 a good or bad ‘guy’ in tumor immunobiology and immunotherapy? Immunol Rev. 2008;222(1):222–41.10.1111/j.1600-065X.2008.00615.x
   PubMed Web of Science ®Google Scholar
• Auron PE. The interleukin 1 receptor: ligand interactions and signal transduction. Cytokine Growth Factor Rev. 1998;9(3–4):221–37.10.1016/S1359-6101(98)00018-5
   PubMed Web of Science ®Google Scholar
• Mantovani A, Muzio M, Ghezzi P, Colotta C, Introna M. Regulation of inhibitory pathways of the interleukin-1 system. Ann N Y Acad Sci. 1998;840:338–51.10.1111/nyas.1998.840.issue-1
   PubMed Web of Science ®Google Scholar
• Stylianou E, Saklatvala J. Interleukin-1. Int J Biochem Cell Biol. 1998;30(10):1075–79.10.1016/S1357-2725(98)00081-8
   PubMed Web of Science ®Google Scholar
• Charmoy M, Hurrell BP, Romano A, Lee SH, Ribeiro-Gomes F, Riteau N, et al. The Nlrp3 inflammasome, IL-1beta, and neutrophil recruitment are required for susceptibility to a nonhealing strain of Leishmania major in C57BL/6 mice. Eur J Immunol. 2016;46(4):897–911.10.1002/eji.201546015
   PubMed Web of Science ®Google Scholar
• Chung Y, Chang SH, Martinez GJ, Yang XO, Nurieva R, Kang HS, et al. Critical regulation of early Th17 cell differentiation by IL-1 signaling. Immunity. 2009;30(4):576–87.10.1016/j.immuni.2009.02.007
   PubMed Web of Science ®Google Scholar
• Lima-Junior DS, Costa DL, Carregaro V, Cunha LD, Silva AL, Mineo TW, et al. Inflammasome-derived IL-1beta production induces nitric oxide-mediated resistance to Leishmania. Nat Med. 2013;19(7):909–15.10.1038/nm.3221
   PubMed Web of Science ®Google Scholar
• Pape KA, Khoruts A, Mondino A, Jenkins MK. Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells. J Immunol. 1997;159(2):591–8.
   PubMed Web of Science ®Google Scholar
• Kostka SL, Knop J, Konur A, Udey MC, von Stebut E. Distinct roles for IL-1 receptor type I Signaling in early versus established Leishmania major infections. J Invest Dermatol. 2006;126(7):1582–9.10.1038/sj.jid.5700309
   PubMed Web of Science ®Google Scholar
• Gurung P, Karki R, Vogel P, Watanabe M, Bix M, Lamkanfi M, et al. An NLRP3 inflammasome-triggered Th2-biased adaptive immune response promotes leishmaniasis. J Clin Invest. 2015;125(3):1329–38.10.1172/JCI79526
   PubMed Web of Science ®Google Scholar
• Gonzalez-Lombana C, Gimblet C, Bacellar O, Oliveira WW, Passos S, Carvalho LP, et al. IL-17 mediates immunopathology in the absence of IL-10 following Leishmania major infection. PLoS Pathog. 2013;9(3):e1003243.10.1371/journal.ppat.1003243
   PubMed Web of Science ®Google Scholar
• Voronov E, Dotan S, Gayvoronsky L, White RM, Cohen I, Krelin Y, et al. IL-1-induced inflammation promotes development of leishmaniasis in susceptible BALB/c mice. Int Immunol. 2010;22(4):245–57.10.1093/intimm/dxq006
   PubMed Web of Science ®Google Scholar
• Kautz-Neu K, Kostka SL, Dinges S, Iwakura Y, Udey MC, von Stebut E. IL-1 signalling is dispensable for protective immunity in Leishmania-resistant mice. Exp Dermatol. 2011;20(1):76–8.10.1111/j.1600-0625.2010.01172.x
   PubMed Web of Science ®Google Scholar
• Ikejima T, Okusawa S, Ghezzi P, Van der Meer JW, Dinarello CA. Interleukin-1 induces tumor necrosis factor (TNF) in human peripheral blood mononuclear cells in vitro and a circulating TNF-like activity in rabbits. J Infect Dis. 1990;162(1):215–23.10.1093/infdis/162.1.215
   PubMed Web of Science ®Google Scholar
• Tsutsui H, Adachi K, Seki E, Nakanishi K. Cytokine-induced inflammatory liver injuries. Curr Mol Med. 2003;3(6):545–59.10.2174/1566524033479618
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Fantuzzi G. Interleukin‐18 and host defense against infection. J Infect Dis. 2003;187(s2):S370–84.10.1086/jid.2003.187.issue-s2
   PubMedGoogle Scholar
• Wei XQ, Leung BP, Niedbala W, Piedrafita D, Feng GJ, Sweet M, et al. Altered immune responses and susceptibility to Leishmania major and Staphylococcus aureus infection in IL-18-deficient mice. J Immunol. 1999;163(5):2821–8.
   PubMed Web of Science ®Google Scholar
• Monteforte GM, Takeda K, Rodriguez-Sosa M, Akira S, David JR, Satoskar AR. Genetically resistant mice lacking IL-18 gene develop Th1 response and control cutaneous Leishmania major infection. J Immunol. 2000;164(11):5890–3.10.4049/jimmunol.164.11.5890
   PubMed Web of Science ®Google Scholar
• Xu D, Trajkovic V, Hunter D, Leung BP, Schulz K, Gracie JA, et al. IL-18 induces the differentiation of Th1 or Th2 cells depending upon cytokine milieu and genetic background. Eur J Immunol. 2000;30(11):3147–56.10.1002/(ISSN)1521-4141
   PubMed Web of Science ®Google Scholar
• Gurung P, Kanneganti T-D. Novel role for inflammasome-dependent IL-18 in promoting Th2 responses during Leishmania infections (IRC7P.420). J Immunol. 2015;194(1 Supplement):128.
   Google Scholar
• Lodolce JP, Burkett PR, Koka RM, Boone DL, Ma A. Regulation of lymphoid homeostasis by interleukin-15. Cytokine Growth Factor Rev. 2002;13(6):429–39.10.1016/S1359-6101(02)00029-1
   PubMed Web of Science ®Google Scholar
• Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science. 1994;264(5161):965–8.10.1126/science.8178155
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001;97(1):14–32.10.1182/blood.V97.1.14
   PubMed Web of Science ®Google Scholar
• Jullien D, Sieling PA, Uyemura K, Mar ND, Rea TH, Modlin RL. IL-15, an immunomodulator of T cell responses in intracellular infection. J Immunol. 1997;158(2):800–06.
   PubMed Web of Science ®Google Scholar
• Carson WE, Ross ME, Baiocchi RA, Marien MJ, Boiani N, Grabstein K, et al. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro. J Clin Invest. 1995;96(6):2578–82.10.1172/JCI118321
   PubMed Web of Science ®Google Scholar
• Waldmann TA, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol. 1999;17:19–49.10.1146/annurev.immunol.17.1.19
   PubMed Web of Science ®Google Scholar
• Lauwerys BR, Garot N, Renauld J-C, Houssiau FA. Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18. J Immunol. 2000;165(4):1847–53.10.4049/jimmunol.165.4.1847
   PubMed Web of Science ®Google Scholar
• Loza MJ, Zamai L, Azzoni L, Rosati E, Perussia B. Expression of type 1 (interferon gamma) and type 2 (interleukin-13, interleukin-5) cytokines at distinct stages of natural killer cell differentiation from progenitor cells. Blood. 2002;99(4):1273–81.10.1182/blood.V99.4.1273
   PubMed Web of Science ®Google Scholar
• D’Agostino P, Milano S, Arcoleo F, Di Bella G, La Rosa M, Ferlazzo V, et al. Interleukin-15, as interferon-gamma, induces the killing of leishmania infantum in phorbol-myristate-acetate-activated macrophages increasing interleukin-12. Scand J Immunol. 2004;60(6):609–14.10.1111/sji.2004.60.issue-6
   PubMed Web of Science ®Google Scholar
• Milano S, Bella G, D’agostino P, Barbera C, Caruso R, Rosa M, et al. IL-15 in human visceral leishmaniasis caused by Leishmania infantum. Clin Exp Immunol. 2002;127(2):360–5.10.1046/j.1365-2249.2002.01749.x
   PubMed Web of Science ®Google Scholar
• Hammond ME, Lapointe GR, Feucht PH, Hilt S, Gallegos CA, Gordon CA, et al. IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors. J Immunol. 1995;155(3):1428–33.
   PubMed Web of Science ®Google Scholar
• Badolato R, Sacks DL, Savoia D, Musso T. Leishmania major:infection of human monocytes induces expression of IL-8 and MCAF. Exp Parasitol. 1996;82(1):21–6.10.1006/expr.1996.0003
   PubMed Web of Science ®Google Scholar
• Müller K, Zandbergen G, Hansen B, Laufs H, Jahnke N, Solbach W, et al. Chemokines, natural killer cells and granulocytes in the early course of Leishmania major infection in mice. Med Microbiol Immunol. 2001;190(1–2):73–6.10.1007/s004300100084
   PubMed Web of Science ®Google Scholar
• Guimaraes-Costa AB, Nascimento MT, Froment GS, Soares RP, Morgado FN, Conceicao-Silva F, et al. Leishmania amazonensis promastigotes induce and are killed by neutrophil extracellular traps. Proc Natl Acad Sci USA. 2009;106(16):6748–53.10.1073/pnas.0900226106
   PubMed Web of Science ®Google Scholar
• Rochael NC, Guimarães-Costa AB, Nascimento MT, DeSouza-Vieira TS, Oliveira MP, Garcia e Souza LF, et al. Classical ROS-dependent and early/rapid ROS-independent release of Neutrophil Extracellular Traps triggered by Leishmania parasites. Sci Rep. 2015;5:18302.10.1038/srep18302
   PubMed Web of Science ®Google Scholar
• Novais FO, Santiago RC, Bafica A, Khouri R, Afonso L, Borges VM, et al. Neutrophils and macrophages cooperate in host resistance against Leishmania braziliensis infection. J Immunol. 2009;183(12):8088–98.10.4049/jimmunol.0803720
   PubMed Web of Science ®Google Scholar
• Carmo ÉVdS, Katz S, Barbiéri CL. Neutrophils reduce the parasite burden in Leishmania (Leishmania) amazonensis-infected macrophages. PLoS ONE. 2010;5(11):e13815.10.1371/journal.pone.0013815
   PubMed Web of Science ®Google Scholar
• Peters NC, Egen JG, Secundino N, Debrabant A, Kimblin N, Kamhawi S, et al. In vivo imaging reveals an essential role for neutrophils in Leishmaniasis transmitted by sand flies. Science. 2008;321(5891):970–4.10.1126/science.1159194
   PubMed Web of Science ®Google Scholar
• Belkaid Y, Mendez S, Lira R, Kadambi N, Milon G, Sacks D. A natural model of Leishmania major infection reveals a prolonged ‘silent’ phase of parasite amplification in the skin before the onset of lesion formation and immunity. J Immunol. 2000;165(2):969–77.10.4049/jimmunol.165.2.969
   PubMed Web of Science ®Google Scholar
• Laufs H, Muller K, Fleischer J, Reiling N, Jahnke N, Jensenius JC, et al. Intracellular survival of Leishmania major in neutrophil granulocytes after uptake in the absence of heat-labile serum factors. Infect Immun. 2002;70(2):826–35.10.1128/IAI.70.2.826-835.2002
   PubMed Web of Science ®Google Scholar
• Scapini P, Lapinet-Vera JA, Gasperini S, Calzetti F, Bazzoni F, Cassatella MA. The neutrophil as a cellular source of chemokines. Immunol Rev. 2000;177:195–203.10.1034/j.1600-065X.2000.17706.x
   PubMed Web of Science ®Google Scholar
• Charmoy M, Brunner-Agten S, Aebischer D, Auderset F, Launois P, Milon G, et al. Neutrophil-Derived CCL3 Is essential for the rapid recruitment of dendritic cells to the site of Leishmania major inoculation in resistant mice. PLoS Pathog. 2010;6(2):e1000755.10.1371/journal.ppat.1000755
   PubMed Web of Science ®Google Scholar
• Ribeiro-Gomes FL, Sacks D. The influence of early neutrophil-Leishmania interactions on the host immune response to infection. Front Cell Infect Microbiol. 2012;2:59. doi:10.3389/fcimb.2012.00059
   PubMed Web of Science ®Google Scholar
• Ribeiro-Gomes FL, Romano A, Lee S, Roffê E, Peters NC, Debrabant A, et al. Apoptotic cell clearance of Leishmania major-infected neutrophils by dendritic cells inhibits CD8(+) T-cell priming in vitro by Mer tyrosine kinase-dependent signaling. Cell Death Dis. 2015;6:e2018.10.1038/cddis.2015.351
   PubMed Web of Science ®Google Scholar
• Van Zandbergen G, Klinger M, Mueller A, Dannenberg S, Gebert A, Solbach W, et al. Cutting edge: neutrophil granulocyte serves as a vector for Leishmania entry into macrophages. J Immunol. 2004;173(11):6521–5.10.4049/jimmunol.173.11.6521
   PubMed Web of Science ®Google Scholar
• Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity. 2004;21(4):467–76.10.1016/j.immuni.2004.08.018
   PubMed Web of Science ®Google Scholar
• McGeachy MJ, Cua DJ. Th17 cell differentiation: the long and winding road. Immunity. 2008;28(4):445–53.10.1016/j.immuni.2008.03.001
   PubMed Web of Science ®Google Scholar
• McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T, et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol. 2007;8(12):1390–7.10.1038/ni1539
   PubMed Web of Science ®Google Scholar
• Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6(11):1133–41.10.1038/ni1261
   PubMed Web of Science ®Google Scholar
• Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123–32.10.1038/ni1254
   PubMed Web of Science ®Google Scholar
• Sutton C, Brereton C, Keogh B, Mills KHG, Lavelle EC. A crucial role for interleukin (IL)-1 in the induction of IL-17–producing T cells that mediate autoimmune encephalomyelitis. J Exp Med. 2006;203(7):1685–91.10.1084/jem.20060285
   PubMed Web of Science ®Google Scholar
• Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, et al. Phenotypic and functional features of human Th17 cells. J Exp Med. 2007;204(8):1849–61.10.1084/jem.20070663
   PubMed Web of Science ®Google Scholar
• Newcomb DC, Zhou W, Moore ML, Goleniewska K, Hershey GK, Kolls JK, et al. A functional IL-13 receptor Is expressed on polarized murine CD4+ Th17 cells and IL-13 signaling attenuates Th17 cytokine production. J Immunol. 2009;182(9):5317–21.10.4049/jimmunol.0803868
   PubMed Web of Science ®Google Scholar
• Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, Lucas S, et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol. 2006;7(9):929–36.10.1038/ni1375
   PubMed Web of Science ®Google Scholar
• Stumhofer JS, Laurence A, Wilson EH, Huang E, Tato CM, Johnson LM, et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol. 2006;7(9):937–45.10.1038/ni1376
   PubMed Web of Science ®Google Scholar
• Kleinschek MA, Owyang AM, Joyce-Shaikh B, Langrish CL, Chen Y, Gorman DM, et al. IL-25 regulates Th17 function in autoimmune inflammation. J Exp Med. 2007;204(1):161–70.10.1084/jem.20061738
   PubMed Web of Science ®Google Scholar
• Lopez Kostka S, Dinges S, Griewank K, Iwakura Y, Udey MC, Von Stebut E. IL-17 promotes progression of cutaneous Leishmaniasis in susceptible mice. J Immunol. 2009;182(5):3039–46.10.4049/jimmunol.0713598
   PubMed Web of Science ®Google Scholar
• Bacellar O, Faria D, Nascimento M, Cardoso TM, Gollob KJ, Dutra WO, et al. Interleukin 17 production among patients with American cutaneous Leishmaniasis. J Infect Dis. 2009;200(1):75–8.10.1086/599173
   PubMed Web of Science ®Google Scholar
• Peters NC, Bertholet S, Lawyer PG, Charmoy M, Romano A, Ribeiro-Gomes FL, et al. Evaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid a stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL/6 mice. J Immunol. 2012;189(10):4832–41.10.4049/jimmunol.1201676
   PubMed Web of Science ®Google Scholar
• Banerjee A, Bhattacharya P, Joshi AB, Ismail N, Dey R, Nakhasi HL. Role of pro-inflammatory cytokine IL-17 in Leishmania pathogenesis and in protective immunity by Leishmania vaccines. Cell Immunol. 2016. doi:10.1016/j.cellimm.2016.07.004
   PubMed Web of Science ®Google Scholar
• Sabat R, Ouyang W, Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov. 2014;13(1):21–38.
   PubMed Web of Science ®Google Scholar
• Rutz S, Eidenschenk C, Ouyang W. IL-22, not simply a Th17 cytokine. Immunol Rev. 2013;252(1):116–32.10.1111/imr.12027
   PubMed Web of Science ®Google Scholar
• Gimblet C, Loesche MA, Carvalho L, Carvalho EM, Grice EA, Artis D, et al. IL-22 protects against tissue damage during cutaneous Leishmaniasis. PLOS ONE. 2015;10(8):e0134698.10.1371/journal.pone.0134698
   PubMed Web of Science ®Google Scholar
• Hezarjaribi HZ, Ghaffarifar F, Dalimi A, Sharifi Z. Evaluation of protective effect of IL-22 and IL-12 on cutaneous leishmaniasis in BALB/c mice. Asian Pacific J Trop Med. 2014;7(12):940–5.10.1016/S1995-7645(14)60166-8
   PubMed Web of Science ®Google Scholar
• Hezarjaribi HZ, Ghaffarifar F, Dalimi A, Sharifi Z, Jorjani O. Effect of IL-22 on DNA vaccine encoding LACK gene of Leishmania major in BALB/c mice. Exp Parasitol. 2013;134(3):341–8.10.1016/j.exppara.2013.03.012
   PubMed Web of Science ®Google Scholar
• Brosch S, Dietze-Schwonberg K, Lopez Kostka S, Lorenz B, Haak S, Becher B, et al. Disease control in cutaneous Leishmaniasis is independent of IL-22. J Invest Dermatol. 2015;135(1):308–11.10.1038/jid.2014.282
   PubMed Web of Science ®Google Scholar
• Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochimica et Biophysica Acta (BBA). Mol Cell Res. 2011;1813(5):878–88.
   PubMed Web of Science ®Google Scholar
• Titus RG, DeKrey GK, Morris RV, Soares MBP. Interleukin-6 deficiency influences cytokine expression in susceptible BALB mice infected with Leishmania major but does not alter the outcome of disease. Infect Immune. 2001;69(8):5189–92.10.1128/IAI.69.8.5189-5192.2001
   PubMed Web of Science ®Google Scholar
• Saha B, Saini A, Germond R, Perrin PJ, Harlan DM, Davis TA. Susceptibility or resistance to Leishmania infection is dictated by the macrophages evolved under the influence of IL-3 or GM-CSF. Eur J Immunol. 1999;29(7):2319–29.10.1002/(ISSN)1521-4141
   PubMed Web of Science ®Google Scholar
• Moskowitz NH, Brown DR, Reiner SL. Efficient immunity against Leishmania major in the absence of interleukin-6. Infect Immun. 1997;65(6):2448–50.
   PubMed Web of Science ®Google Scholar
• Hatzigeorgiou DE, He S, Sobel J, Grabstein KH, Hafner A, Ho J. IL-6 down-modulates the cytokine-enhanced antileishmanial activity in human macrophages. J Immunol. 1993;151(7):3682–92.
   PubMed Web of Science ®Google Scholar
• Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol. 2007;25:221–42.10.1146/annurev.immunol.22.012703.104758
   PubMed Web of Science ®Google Scholar
• Hunter CA, Villarino A, Artis D, Scott P. The role of IL-27 in the development of T-cell responses during parasitic infections. Immunol Rev. 2004;202(1):106–14.10.1111/imr.2004.202.issue-1
   PubMed Web of Science ®Google Scholar
• Villarino AV, Huang E, Hunter CA. Understanding the pro- and anti-inflammatory properties of IL-27. J Immunol. 2004;173(2):715–20.10.4049/jimmunol.173.2.715
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Takeda A, Hamano S, Miyazaki Y, Kinjyo I, Ishibashi T, et al. Two-sided roles of IL-27: induction of Th1 differentiation on naive CD4+ T cells versus suppression of proinflammatory cytokine production including IL-23-induced IL-17 on activated CD4+ T cells partially through STAT3-dependent mechanism. J Immunol. 2006;177(8):5377–85.
   PubMed Web of Science ®Google Scholar
• Murugaiyan G, Mittal A, Lopez-Diego R, Maier LM, Anderson DE, Weiner HL. IL-27 is a key regulator of IL-10 and IL-17 production by human CD4+ T cells. J Immunol. 2009;183(4):2435–43.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Hamano S, Senaldi G, Covey T, Faggioni R, Mu S, et al. WSX-1 Is required for the initiation of Th1 responses and resistance to L. major infection. Immunity. 2001;15(4):569–78.10.1016/S1074-7613(01)00206-0
   PubMed Web of Science ®Google Scholar
• Artis D, Johnson LM, Joyce K, Saris C, Villarino A, Hunter CA, et al. Cutting edge: early IL-4 production governs the requirement for IL-27-WSX-1 signaling in the development of protective Th1 cytokine responses following Leishmania major infection. J Immunol. 2004;172(8):4672–5.10.4049/jimmunol.172.8.4672
   PubMed Web of Science ®Google Scholar
• Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature. 2002;420(6915):502–7.10.1038/nature01152
   PubMed Web of Science ®Google Scholar
• Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765.10.1146/annurev.immunol.19.1.683
   PubMed Web of Science ®Google Scholar
• Saraiva M, O’Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10(3):170–81.10.1038/nri2711
   PubMed Web of Science ®Google Scholar
• Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol. 2001;2(9):816–22.10.1038/ni0901-816
   PubMed Web of Science ®Google Scholar
• O’Garra A, Vieira P. T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol. 2007;7(6):425–8.10.1038/nri2097
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin-10 production by effector T cells: Th1 cells show self control. J Exp Med. 2007;204(2):239–243.10.1084/jem.20070104
   PubMed Web of Science ®Google Scholar
• O’Garra A, Vieira P. TH1 cells control themselves by producing interleukin-10. Nat Rev Immunol. 2007;7(6):425–8.10.1038/nri2097
   PubMed Web of Science ®Google Scholar
• Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, Wynn TA, et al. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of Anti–IL-10 receptor antibody for sterile cure. J Exp Med. 2001;194(10):1497–1506.10.1084/jem.194.10.1497
   PubMed Web of Science ®Google Scholar
• Anderson CF, Mendez S, Sacks DL. Nonhealing infection despite Th1 polarization produced by a strain of Leishmania major in C57BL/6 mice. J Immunol. 2005;174(5):2934–41.10.4049/jimmunol.174.5.2934
   PubMed Web of Science ®Google Scholar
• Castellano LR, Filho DC, Argiro L, Dessein H, Prata A, Dessein A, et al. Th1/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon-gamma production. Hum Immunol. 2009;70(6):383–390.10.1016/j.humimm.2009.01.007
   PubMed Web of Science ®Google Scholar
• Salhi A, Rodrigues V Jr, Santoro F, Dessein H, Romano A, Castellano LR, et al. Immunological and genetic evidence for a crucial role of IL-10 in cutaneous lesions in humans infected with Leishmania braziliensis. J Immunol. 2008;180(9):6139–48.10.4049/jimmunol.180.9.6139
   PubMed Web of Science ®Google Scholar
• Buxbaum LU, Scott P. Interleukin 10- and Fcγ receptor-deficient mice resolve Leishmania mexicana lesions. Infect Immune. 2005;73(4):2101–08.10.1128/IAI.73.4.2101-2108.2005
   PubMed Web of Science ®Google Scholar
• Stober CB, Lange UG, Roberts MT, Alcami A, Blackwell JM. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection. J Immunol. 2005;175(4):2517–24.10.4049/jimmunol.175.4.2517
   PubMed Web of Science ®Google Scholar
• Darrah PA, Hegde ST, Patel DT, Lindsay RW, Chen L, Roederer M, et al. IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. J Exp Med. 2010;207(7):1421–33.10.1084/jem.20092532
   PubMed Web of Science ®Google Scholar
• Gomes-Silva A, De Cássia Bittar R, Dos Santos Nogueira R, Amato VS, Da Silva Mattos M, Oliveira-Neto MP, et al. Can interferon-γ and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection? Clin Exp Immunol. 2007;149(3):440–4.10.1111/j.1365-2249.2007.03436.x
   PubMed Web of Science ®Google Scholar
• Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531–62.10.1146/annurev.immunol.21.120601.141122
   PubMed Web of Science ®Google Scholar
• Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med. 2001;194(5):629–44.10.1084/jem.194.5.629
   PubMed Web of Science ®Google Scholar
• Wan YY, Flavell RA. ‘Yin-Yang’ functions of TGF-β and Tregs in immune regulation. Immunol Rev. 2007;220:199–213.10.1111/imr.2007.220.issue-1
   PubMed Web of Science ®Google Scholar
• Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol. 2002;2(6):389–400.
   PubMed Web of Science ®Google Scholar
• Vieira PL, Christensen JR, Minaee S, O’Neill EJ, Barrat FJ, Boonstra A, et al. IL-10-secreting regulatory T cells do not express foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol. 2004;172(10):5986–93.10.4049/jimmunol.172.10.5986
   PubMed Web of Science ®Google Scholar
• Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunol Rev. 2001;182:68–79.10.1034/j.1600-065X.2001.1820105.x
   PubMed Web of Science ®Google Scholar
• Stassen M, Fondel S, Bopp T, Richter C, Müller C, Kubach J, et al. Human CD25+ regulatory T cells: two subsets defined by the integrins alpha 4 beta 7 or alpha 4 beta 1 confer distinct suppressive properties upon CD4+ T helper cells. Eur J Immunol. 2004;34(5):1303–11.10.1002/(ISSN)1521-4141
   PubMed Web of Science ®Google Scholar
• Weiner HL. Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol Rev. 2001;182:207–14.10.1034/j.1600-065X.2001.1820117.x
   PubMed Web of Science ®Google Scholar
• Anderson CF, Oukka M, Kuchroo VJ, Sacks D. CD4(+)CD25(−)Foxp3(−) Th1 cells are the source of IL-10–mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med. 2007;204(2):285–97.10.1084/jem.20061886
   PubMed Web of Science ®Google Scholar
• Castellano LR, Argiro L, Dessein H, Dessein A, da Silva MV, Correia D, et al. Potential use of interleukin-10 blockade as a therapeutic strategy in human cutaneous Leishmaniasis. J Immunol Res. 2015;2015:5, Article ID 152741. doi:10.1155/2015/152741
   Web of Science ®Google Scholar
• Kopf M, Gros G, Bachmann M, Lamers M, Bluethmann H, Köhler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature. 1993;362(6417):245–8.10.1038/362245a0
   PubMed Web of Science ®Google Scholar
• Zamorano J, Rivas M, Perez G. Interleukin-4: a multifunctional cytokine. Immunologia. 2003;22(2):215–24.
   Google Scholar
• Paul WE. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood. 1991;77(9):1859–70.
   PubMed Web of Science ®Google Scholar
• Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3(1):23–35.10.1038/nri978
   PubMed Web of Science ®Google Scholar
• Szabo SJ, Dighe AS, Gubler U, Murphy KM. Regulation of the interleukin (IL)-12R β2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J Exp Med. 1997;185(5):817–24.10.1084/jem.185.5.817
   PubMed Web of Science ®Google Scholar
• Lazarski CA, Ford J, Katzman SD, Rosenberg AF, Fowell DJ. IL-4 attenuates Th1-associated chemokine expression and Th1 trafficking to inflamed tissues and limits pathogen clearance. PLoS ONE. 2013;8(8):e71949.10.1371/journal.pone.0071949
   PubMed Web of Science ®Google Scholar
• Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32(5):593–604.10.1016/j.immuni.2010.05.007
   PubMed Web of Science ®Google Scholar
• Munder M, Eichmann K, Modolell M. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol. 1998;160(11):5347–54.
   PubMed Web of Science ®Google Scholar
• Munder M, Eichmann K, Moran JM, Centeno F, Soler G, Modolell M. Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol. 1999;163(7):3771–7.
   PubMed Web of Science ®Google Scholar
• Hesse M, Modolell M, La Flamme AC, Schito M, Fuentes JM, Cheever AW, et al. Differential regulation of nitric oxide synthase-2 and arginase-1 by Type 1/Type 2 cytokines in vivo: granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol. 2001;167(11):6533–44.10.4049/jimmunol.167.11.6533
   PubMed Web of Science ®Google Scholar
• Kopf M, Brombacher F, Kohler G, Kienzle G, Widmann KH, Lefrang K, et al. IL-4-deficient Balb/c mice resist infection with Leishmania major. J Exp Med. 1996;184(3):1127–36.10.1084/jem.184.3.1127
   PubMed Web of Science ®Google Scholar
• Radwanska M, Cutler AJ, Hoving JC, Magez S, Holscher C, Bohms A, et al. Deletion of IL-4ralpha on CD4 T cells renders BALB/c mice resistant to Leishmania major infection. PLoS Pathog. 2007;3(5):e68.10.1371/journal.ppat.0030068
   PubMed Web of Science ®Google Scholar
• Sadick MD, Heinzel FP, Holaday BJ, Pu RT, Dawkins RS, Locksley RM. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism. J Exp Med. 1990;171(1):115–27.10.1084/jem.171.1.115
   PubMed Web of Science ®Google Scholar
• Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med. 1989;169(1):59–72.10.1084/jem.169.1.59
   PubMed Web of Science ®Google Scholar
• Noben-Trauth N, Paul WE, Sacks DL. IL-4- and IL-4 receptor-deficient BALB/c mice reveal differences in susceptibility to Leishmania major parasite substrains. J Immunol. 1999;162(10):6132–6140.
   PubMed Web of Science ®Google Scholar
• Noben-Trauth N, Kropf P, Muller I. Susceptibility to Leishmania major Infection in Interleukin-4-deficient mice. Science. 1996;271(5251):987–90.10.1126/science.271.5251.987
   PubMed Web of Science ®Google Scholar
• Alexander J, Brombacher F, McGachy HA, McKenzie AN, Walker W, Carter KC. An essential role for IL-13 in maintaining a non-healing response following Leishmania mexicana infection. Eur J Immunol. 2002;32(10):2923–33.10.1002/1521-4141(2002010)32:10<2923::AID-IMMU2923>3.0.CO;2-E
   PubMed Web of Science ®Google Scholar
• Scott P, Eaton A, Gause WC, di Zhou X, Hondowicz B. Early IL-4 production does not predict susceptibility to Leishmania major. Exp Parasitol. 1996;84(2):178–87.10.1006/expr.1996.0103
   PubMed Web of Science ®Google Scholar
• Kropf P, Herath S, Weber V, Modolell M, Muller I. Factors influencing Leishmania major infection in IL-4-deficient BALB/c mice. Parasite Immunol. 2003;25(8–9):439–47.10.1111/pim.2003.25.issue-8-9
   PubMed Web of Science ®Google Scholar
• Chomarat P, Banchereau J. Interleukin-4 and interleukin-13: their similarities and discrepancies. Int Rev Immunol. 1998;17(1–4):1–52.10.3109/08830189809084486
   PubMedGoogle Scholar
• de Waal Malefyt R, Figdor CG, Huijbens R, Mohan-Peterson S, Bennett B, Culpepper J, et al. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J Immunol. 1993;151(11):6370–81.
   PubMed Web of Science ®Google Scholar
• Doherty TM, Kastelein R, Menon S, Andrade S, Coffman RL. Modulation of murine macrophage function by IL-13. J Immunol. 1993;151(12):7151–60.
   PubMed Web of Science ®Google Scholar
• Oswald IP, Gazzinelli RT, Sher A, James SL. IL-10 synergizes with IL-4 and transforming growth factor-beta to inhibit macrophage cytotoxic activity. J Immunol. 1992;148(11):3578–82.
   PubMed Web of Science ®Google Scholar
• Doherty TM, Kastelein R, Menon S, Andrade S, Coffman RL. Modulation of murine macrophage function by IL-13. J Immunol. 1993;151(12):7151–60.
   PubMed Web of Science ®Google Scholar
• Matthews DJ, Emson CL, McKenzie GJ, Jolin HE, Blackwell JM, McKenzie AN. IL-13 Is a susceptibility factor for Leishmania major infection. J Immunol. 2000;164(3):1458–62.10.4049/jimmunol.164.3.1458
   PubMed Web of Science ®Google Scholar
• Saura M, Martinez-Dalmau R, Minty A, Perez-Sala D, Lamas S. Interleukin-13 inhibits inducible nitric oxide synthase expression in human mesangial cells. Biochem J. 1996;313(2):641–6.10.1042/bj3130641
   PubMed Web of Science ®Google Scholar
• Bourreau E, Prévot G, Pradinaud R, Launois P. Interleukin (IL)–13 Is the predominant Th2 cytokine in localized cutaneous Leishmaniasis lesions and renders specific CD4+ T cells unresponsive to IL-12. J Infect Dis. 2001;183(6):953–9.10.1086/jid.2001.183.issue-6
   PubMed Web of Science ®Google Scholar
• Sosa MR, Rosas LE, McKenzie AN, Satoskar AR. IL-13 gene-deficient mice are susceptible to cutaneous L. mexicana infection. Eur J Immunol. 2001;31(11):3255–60.10.1002/(ISSN)1521-4141
   PubMed Web of Science ®Google Scholar
• Hansen G, McIntire JJ, Yeung VP, Berry G, Thorbecke GJ, Chen L, et al. CD4+ T helper cells engineered to produce latent TGF-β1 reverse allergen-induced airway hyperreactivity and inflammation. J Clin Invest. 2000; 105(1):61–7.
   PubMed Web of Science ®Google Scholar
• Grotendorst GR, Smale G, Pencev D. Production of transforming growth factor beta by human peripheral blood monocytes and neutrophils. J Cell Physiol. 1989;140(2):396–402.10.1002/(ISSN)1097-4652
   PubMed Web of Science ®Google Scholar
• Tran DQ. TGF-β: the sword, the wand, and the shield of FOXP3+ regulatory T cells. J Cell Mol Biol. 2012; 4(1): 29–37.
   PubMed Web of Science ®Google Scholar
• Gorelik L, Flavell RA. Transforming growth factor-[beta] in T-cell biology. Nat Rev Immunol. 2002;2(1):46–53.10.1038/nri704
   PubMed Web of Science ®Google Scholar
• Speck S, Lim J, Shelake S, Matka M, Stoddard J, Farr A, et al. TGF-β signaling initiated in dendritic cells instructs suppressive effects on Th17 differentiation at the site of neuroinflammation. PLoS ONE. 2014;9(7):e102390.10.1371/journal.pone.0102390
   PubMed Web of Science ®Google Scholar
• Huber S, Schramm C. TGF-beta and CD4+CD25+ regulatory T cells. Front Biosci. 2006;11:1014–23.10.2741/1859
   PubMed Web of Science ®Google Scholar
• Fu S, Zhang N, Yopp AC, Chen D, Mao M, Chen D, et al. TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 – precursors. Am J Transplant. 2004;4(10):1614–27.10.1111/ajt.2004.4.issue-10
   PubMed Web of Science ®Google Scholar
• Laouar Y, Sutterwala FS, Gorelik L, Flavell RA. Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma. Nat Immunol. 2005;6(6):600–07.10.1038/ni1197
   PubMed Web of Science ®Google Scholar
• Lucas PJ, Kim SJ, Melby SJ, Gress RE. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor. J Exp Med. 2000;191(7):1187–96.10.1084/jem.191.7.1187
   PubMed Web of Science ®Google Scholar
• Nakao A, Miike S, Hatano M, Okumura K, Tokuhisa T, Ra C, et al. Blockade of transforming growth factor beta/Smad signaling in T cells by overexpression of Smad7 enhances antigen-induced airway inflammation and airway reactivity. J Exp Med. 2000;192(2):151–8.10.1084/jem.192.2.151
   PubMed Web of Science ®Google Scholar
• Gorelik L, Fields PE, Flavell RA. Cutting edge: TGF-beta inhibits Th type 2 development through inhibition of GATA-3 expression. J Immunol. 2000;165(9):4773–7.10.4049/jimmunol.165.9.4773
   PubMed Web of Science ®Google Scholar
• Sad S, Mosmann TR. Single IL-2-secreting precursor CD4 T cell can develop into either Th1 or Th2 cytokine secretion phenotype. J Immunol. 1994;153(8):3514–22.
   PubMed Web of Science ®Google Scholar
• Wahl SM, Hunt DA, Wong HL, Dougherty S, McCartney-Francis N, Wahl LM, et al. Transforming growth factor-beta is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol. 1988;140(9):3026–32.
   PubMed Web of Science ®Google Scholar
• Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med. 1986;163(5):1037–50.10.1084/jem.163.5.1037
   PubMed Web of Science ®Google Scholar
• Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med. 2003;198(12):1875–86.10.1084/jem.20030152
   PubMed Web of Science ®Google Scholar
• Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature. 1992;359(6397):693–9.10.1038/359693a0
   PubMed Web of Science ®Google Scholar
• Li MO, Sanjabi S, Flavell RA. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity. 2006;25(3):455–71.10.1016/j.immuni.2006.07.011
   PubMed Web of Science ®Google Scholar
• Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med. 2005;201(7):1061–7.10.1084/jem.20042276
   PubMed Web of Science ®Google Scholar
• Barral A, Teixeira M, Reis P, Vinhas V, Costa J, Lessa H, et al. Transforming growth factor-beta in human cutaneous leishmaniasis. Am J Path. 1995;147(4):947–54.
   PubMed Web of Science ®Google Scholar
• Kedzierski L, Evans KJ. Immune responses during cutaneous and visceral leishmaniasis. Parasitology. 2014;141(12):1–19.
   PubMed Web of Science ®Google Scholar
• Gorelik L, Constant S, Flavell RA. Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J Exp Med. 2002;195(11):1499–505.10.1084/jem.20012076
   PubMed Web of Science ®Google Scholar
• Barral A, Teixeira M, Reis P, Vinhas V, Costa J, Lessa H, et al. Transforming growth factor-beta in human cutaneous leishmaniasis. Am J Pathol. 1995;147(4):947–54.
   PubMed Web of Science ®Google Scholar
• Barral-Netto M, Barral A. Transforming growth factor-beta in tegumentary leishmaniasis. Braz J Med Biol Res. 1994;27(1):1–9.
   PubMed Web of Science ®Google Scholar
• Barral A, Barral-Netto M, Yong EC, Brownell CE, Twardzik DR, Reed SG. Transforming growth factor beta as a virulence mechanism for Leishmania braziliensis. Proc Natl Acad Sci U S A. 1993;90(8):3442–6.10.1073/pnas.90.8.3442
   PubMed Web of Science ®Google Scholar
• Li J, Hunter CA, Farrell JP. Anti-TGF-beta treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production. J Immunol. 1999;162(2):974–9.
   PubMed Web of Science ®Google Scholar
• Melby PC, Andrade-Narvaez FJ, Darnell BJ, Valencia-Pacheco G, Tryon VV, Palomo-Cetina A. Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect. Immun. 1994;62(3):837–42.
   PubMed Web of Science ®Google Scholar
• Diaz NL, Zerpa O, Ponce LV, Convit J, Rondon AJ, Tapia FJ. Intermediate or chronic cutaneous leishmaniasis: leukocyte immunophenotypes and cytokine characterisation of the lesion. Exp Dermatol. 2002;11(1):34–41.10.1034/j.1600-0625.2002.110104.x
   PubMed Web of Science ®Google Scholar
• Hejazi S, Hoseini S, Javanmard S, Zarkesh S, Khamesipour A. Interleukin-10 and transforming growth factor-beta in early and late lesions of patients with Leishmania major induced cutaneous Leishmaniasis. Iran J Parasitol. 2012;7(2):53–60.
   PubMed Web of Science ®Google Scholar
• Tsunawaki S, Sporn M, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor-beta. Nature. 1988;334(6179):260–2.10.1038/334260a0
   PubMed Web of Science ®Google Scholar
• Takaki H, Minoda Y, Koga K, Takaesu G, Yoshimura A, Kobayashi T. TGF-β1 suppresses IFN-γ-induced NO production in macrophages by suppressing STAT1 activation and accelerating iNOS protein degradation. Gene Cell. 2006;11(8):871–82.10.1111/gtc.2006.11.issue-8
   PubMed Web of Science ®Google Scholar
• Volpe E, Servant N, Zollinger R, Bogiatzi SI, Hupé P, Barillot E, et al. A critical function for transforming growth factor-β, interleukin 23 and proinflammatory cytokines in driving and modulating human TH-17 responses. Nat Immunol. 2008;9(6):650–7.10.1038/ni.1613
   PubMed Web of Science ®Google Scholar
• Nylén S, Eidsmo L. Tissue damage and immunity in cutaneous leishmaniasis. Parasit Immunol. 2012;34(12):551–61.10.1111/pim.12007
   PubMed Web of Science ®Google Scholar